SCHEMBL17465718

SCHEMBL17465718

Cc1cc(C(=O)Nc2ccc(F)c(F)c2)ccc1F

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.64
RAB9A P51151 3/20 0.64
KCNQ3 O43525 5/20 0.61
KCNQ2 O43526 5/20 0.61
MAOB P27338 4/20 0.59
LMNA P02545 1/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
MAOA P21397 1/20 0.56
KCNE1 P15382 2/20 0.54
KCNQ1 P51787 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KCNQ5 Q9NR82 1/20 0.52
HTR2B P41595 1/20 0.52
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
IDO1 P14902 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17784128 0.85 NPC1 (0.57) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL25485683 0.84 KMT2A (0.56) NPC1RAB9A
SCHEMBL19479148 0.83 KCNQ3 (0.50) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL17803501 0.83 KCNQ3 (0.50) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL17465706 0.83 NPC1 (0.62) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL8361564 0.82 NPC1 (0.68) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL10192542 0.82 MEN1 (0.53)
SCHEMBL20577784 0.82 HDAC1 (0.52) NPC1RAB9AKCNQ3KCNQ2LMNA
SCHEMBL17936108 0.82 KIT (0.50) NPC1RAB9AKCNQ3KCNQ2MAOB
SCHEMBL15847328 0.81 NPC1 (0.64) NPC1RAB9AKCNQ3KCNQ2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 US disclosed
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION HAVCR2, EIF2AK2, NR1H4 NPC1 272/4885RAB9A 3576/4885KCNQ3 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.